The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Health Canada ...
April 28 (Reuters) - Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tab blockbuster diabetes drug Ozempic made by Indian drugmaker Dr ...
Health Canada has approved the first generic version of brand-name Ozempic. The department says Canada is the first G7 country to authorize generic semaglutide. The injectable medication is ...
NEW DELHI: A wave of affordable generic versions of Ozempic and Wegovy (semaglutide) has rapidly captured around 20% of the nearly Rs 1,600 crore weight-loss market within days of launch, following ...
Multiple dapagliflozin generic approvals are expected to intensify near-term market competition, requiring manufacturers to coordinate production readiness, launch timing, and labeling compliance ...
The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...
Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...
John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. Lizzy Lawrence leads STAT’s ...
Patients in Canada have been paying between $300 and $400 a month for Ozempic and Wegovy, depending on the prescribed dose You can save this article by registering for free here. Or sign-in if you ...
At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results